Eli Lilly's Migraine Candidate Flunks Head-To-Head Study With Pfizer's Newly Acquired Drug
Portfolio Pulse from Vandana Singh
Eli Lilly's Emgality failed to meet the primary endpoint in a head-to-head study with Pfizer's Nurtec ODT for migraine treatment. Emgality did not show statistical superiority in reducing monthly migraine headache days by 50% or more. Pfizer acquired Nurtec ODT after buying Biohaven Pharmaceutical for $11.6 billion.
June 16, 2023 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's Emgality failed to meet the primary endpoint in a head-to-head study with Pfizer's Nurtec ODT, potentially impacting its competitive position in the migraine treatment market.
Eli Lilly's Emgality did not show statistical superiority in reducing monthly migraine headache days by 50% or more compared to Pfizer's Nurtec ODT. This could negatively impact Eli Lilly's competitive position in the migraine treatment market, as it may struggle to gain market share against Pfizer's product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer's Nurtec ODT outperformed Eli Lilly's Emgality in a head-to-head study, potentially strengthening its position in the migraine treatment market.
Pfizer's Nurtec ODT showed better results than Eli Lilly's Emgality in a head-to-head study, potentially strengthening its position in the migraine treatment market. This could lead to increased market share and sales for Pfizer's product, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100